Organon Pharma Indonesia Tbk. vs Sumber Mineral Global Abadi Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Sumber Mineral Global Abadi Tbk. trades at Rp88 (market cap 778.75B, 4.75M 24h volume). The key difference: Sumber Mineral Global Abadi Tbk. is far larger — about 7.5× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SMGA | |
|---|---|---|
Market Cap | 104.4B | 778.75B |
Volume | — | 4.75M |
Lot | — | 47.55K |
Turnover | — | 416.69M |
Average Price | — | 87.64 |
Value | — | 416.69M |
Indicative Equilibrium Price | — | 88 |
Indicative Equilibrium Volume | — | 407 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Sumber Mineral Global Abadi Tbk (the Company) was established based on Notarial Deed No. 2 dated October 19, 2016 of Selina Bertha Eny, S.H., a notary in South Tanggerang. The Company started its commercial operations in 2016. The Company’s immediate and ultimate parententities are PT Sumber Global Energy Tbk and PT Sumbermas Inti Energi, respectively, both entities domiciled in Jakarta. The controlling interest of the Company is PT Sumber Global Energy Tbk.
Read more on SMGA →